1 October 2020 in International Journal of Surgery
Good management of disposable and reusable supplies may improve surgical efficiency in the operating room (OR) and also corresponds to the best eco-responsible approach. The purpose of this study was to assess the impact of a clinical pharmacist's intervention in the OR on the non-compliant use of medical devices. We also assessed the economic impact of the pharmaceutical intervention. We conducted a monocentric prospective study in the OR of a University hospital over one year. Three surgical specialties: urologic, digestive and gynecologic were audited after a preparatory phase to optimize usage of medical devices used for surgeries. The supply costs concerning the three specialties were compared before and after the pharmacist intervention. One hundred and fifty surgical procedures were audited in digestive (33.3%, n = 50), gynecologic (32%, n = 48) and urologic (34.7%, n = 52) surgeries. With the pharmacist in OR, 51 procedures (34% CI95%[26.4%; 41.6%]) with a non-compliance concerning at least one medical device were found compared to the 50% rate without the pharmacist reported previously (P < .0001). Eighteen percent of surgical procedures had at least one circulator retrieval for the reason "incomplete case cart despite device listed on the case cart list" versus 29.1% before pharmacist intervention (P = .0028). A €33 014 saving associated with the presence of the pharmacist in OR was observed. This prospective interventional study showed that the intervention of a pharmacist specialized in the medical device field could significantly reduce non-compliances in medical device use and reduce costs in OR.
4 February 2026 in BMJ Open
Introduction: Fever is the leading reason for consultation among children in general practice. 20% of febrile children require additional tests to distinguish between viral infections and severe bacterial infections. Point of care capillary C-reactive protein (POC CRP) testing provides on-site results within 5 min but remains underutilised in primary care settings in France. This study will demonstrate how the use of POC CRP could optimise the care pathway for febrile children, saving time for physicians and patients, and making economic savings. Methods and analysis: This is a multicentre, prospective, cluster-randomised stepped-wedge trial that will take place from September 2025 to March 2026. The required sample size is estimated at 420 patients. The primary outcome is the difference in referral rates to facilities equipped for emergency laboratory testing (medical biology laboratories, emergency departments) when using POC CRP versus standard care. The study will be conducted in primary care practices and out-of-hours clinics in south France among febrile children aged 3 months to 15 years, over the 6-month viral and bacterial epidemic period. A cost-consequence analysis and a budget impact assessment will also be performed. Ethics and dissemination: The protocol was approved by the Ile de France VII Committee for the Protection of Persons (2024-A02844-43), the French Advisory Board on Medical Research Data Processing and the French Personal Data Protection Authority. The study was prospectively registered on clinicaltrials.gov. Trial registration number: NCT06910631 .
4 August 2026 in International Journal of Technology Assessment in Health Care
Objectives: The objective of this study is to examine current practices regarding the integration of environmental and economic impact assessments in decision making for medical device procurement across French healthcare facilities. These findings will reveal the barriers to environmental criteria integration in Hospital-Based Health Technology Assessment (HB-HTA). Methods: A cross-sectional survey, collected between 21 May and 12 July 2024, explored knowledge and implementation of environmental and economic assessments in hospital-based medical device procurement. Disseminated nationwide through the French Interregional Clinical Research and Innovation Groups (GIRCI), the French National Agency for Support to Healthcare Performance (ANAP) network, and via Territorial Hospital Groups, targeting public and private healthcare centers, the eight-section survey addressed governance, eco-responsible procurement, environmental data accessibility, and experience with joint assessments and certification practices. Results: Twenty-nine healthcare centers were analyzed, mostly regional or university hospitals or community hospitals (88 percent), primarily in the public sector. A structured approach to ecological transition was reported by 76 percent of institutions. Eco-responsible purchasing measures were implemented in nineteen centers (83 percent); however, access to life-cycle assessment data, especially for upstream manufacturing phases, remained limited. Forty-five percent of institutions had conducted joint environmental-economic assessments. Although 70 percent of respondents were aware of responsible procurement certifications schemes, only 36 percent used them. Conclusions: French healthcare institutes demonstrate growing awareness and engagement in sustainable procurement practices. However, limited access to standardized environmental data blocks systematic integration of environmental criteria into procurement practices and thus HB-HTA. Strengthening supplier transparency, harmonizing evaluation frameworks, and embedding environmental metrics into both processes could accelerate sustainable transition.
20 December 2023 in Contemporary Clinical Trials Communications
GLGéraldine Leguelinel-Blache
Géraldine Leguelinel-Blache
+2
Chronic obstructive pulmonary disease (COPD) is an irreversible chronic respiratory disease which outcome depends on medication adherence. Pharmacists may increase this adherence by advising patients on inhaler devices proper use. This paper presents the protocol for a randomized controlled trial, which assesses impact of pharmaceutical consultations on COPD exacerbations, medical care, adherence to inhaler devices and quality of life. This trial will include 226 COPD patients treated with inhaler devices: 94 in a control group, 66 receiving a pharmaceutical consultation at hospital and 66 receiving up to 12 pharmaceutical consultations corresponding to dispensing at their community pharmacy. The aim of these interventions is to inform patients about COPD medication, train them in the use of inhaler devices and improve adherence. Patients included by hospital pharmacist will be randomly assigned to the control and hospital experimental groups. Community pharmacists (CP) will include patients in the experimental community group. CPs will follow-up all study patients for 12 months. Primary outcome is the mean number of COPD exacerbations. Secondary outcomes include number of medical consultations, emergency visits and hospitalizations, patients’ adherence devices and quality of life. This is the first French trial which assesses both hospital and community pharmaceutical interventions on COPD patients. Study limitations include recruitment and CP adherence to follow-up. Indeed, the success of this trial depends on the willingness of CPs to collect the data. This work is the first step towards building a network of CPs trained for clinical research. Clinicaltrials.gov, NCT03704545. Registered on October 12th, 2018. https://clinicaltrials.gov/ct2/show/NCT03704545?cond=COPD&cntry=FR&city=nimes&draw=2&rank=1.